TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7951125

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500 mg orally twice a day plus antifungal prophylaxis (fluconazole 50 mg once daily plus amphotericin B 200 mg four times a day) and streptococcal prophylaxis for 10 days after BMT
Number of subjects: 113

Group type: COMPARATOR
Intervention: Protective isolation
Number of subjects: 113
Study: 31402293

Group type: EXPERIMENTAL
Intervention: 50,000 units VitD3 capsules every week for 7 weeks
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Single dose of 300,000 units VitD3 ampoule
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Combination of half of the injection dose followed by oral capsule for 4 weeks
Number of subjects: 100
Study: 28597922

Group type: EXPERIMENTAL
Intervention: 5 mg DFN-02
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 10 mg DFN-02
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 15 mg DFN-02
Number of subjects: 18

Group type: COMPARATOR
Intervention: 6 mg subcutaneous sumatriptan injection
Number of subjects: 18
Study: 25204557

Group type: COMPARATOR
Intervention: 10 mg oral lenvatinib (5 mg for severe hepatic impairment)
Number of subjects: 26
Study: 22901697

Group type: EXPERIMENTAL
Intervention: Midlife hypertension
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Continuous decline in systolic BP and increase in pulse pressure
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Decline in systolic BP starting at older ages
Number of subjects: 63

Group type: COMPARATOR
Intervention: Body mass index, cholesterol, or apolipoprotein E ε4 allele
Number of subjects: 63
Study: 22068930

Group type: EXPERIMENTAL
Intervention: sports-cADHD (90-min athletic activity, twice a week for 6 weeks)
Number of subjects: 28

Group type: COMPARATOR
Intervention: edu-cADHD (education on behavior control)
Number of subjects: 28
Study: 18551282

Group type: EXPERIMENTAL
Intervention: Intravenous allopregnanolone
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 16490806

Group type: EXPERIMENTAL
Intervention: Dapoxetine 30 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dapoxetine 60 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dapoxetine (both doses)
Number of subjects: 0
Study: 12390425

Group type: EXPERIMENTAL
Intervention: Serum cystatin C
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Serum creatinine
Number of subjects: 19

Group type: COMPARATOR
Intervention: Serum cystatin C and serum creatinine
Number of subjects: 19
Study: 10429599

Group type: EXPERIMENTAL
Intervention: Reorientation measures during the perioperative phase (including presurgery admission to the orthopedic ward, home visits, access to reorientation devices such as a large clock, calendar, radio, TV-set, telephone, and encouragement to wear own clothing)
Number of subjects: 223

Group type: COMPARATOR
Intervention: Control group (standard treatment without reorientation measures)
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Both groups (reorientation measures vs control)
Number of subjects: 223
Study: 7739278

Group type: EXPERIMENTAL
Intervention: C-reactive protein serum levels in primary thrombocytosis group (27 patients)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: C-reactive protein serum levels in secondary thrombocytosis group (62 patients)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Normal controls (54 patients)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Comparison of C-reactive protein levels between groups
Number of subjects: 89
Study: 1697283

Group type: EXPERIMENTAL
Intervention: 5% human albumin
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 10% hydroxyethyl starch (HAES-steril)
Number of subjects: 40
Study: 6457152

Group type: EXPERIMENTAL
Intervention: 30 mg of the alpha-blocker thymoxamine given by inhalation
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31577692

Group type: EXPERIMENTAL
Intervention: Early enteral nutrition
Number of subjects: 608
Study: 30087199

Group type: EXPERIMENTAL
Intervention: T/A group (adenotonsillectomy)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control group (usual waiting period for surgery)
Number of subjects: 140
Study: 27591461

Group type: EXPERIMENTAL
Intervention: Paravertebral block with single needle prick in T4 with 0.5% ropivacaine+adrenaline 3μgmL(‐1) with a volume of 0.3mLkg(‐1) preoperatively
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Paravertebral block
Number of subjects: 80
Study: 25410412

Group type: EXPERIMENTAL
Intervention: Sexual assault resistance education program
Number of subjects: 899
Study: 22677643

Group type: EXPERIMENTAL
Intervention: Topical pranoprofen 0.1% plus topical sodium hyaluronate 0.1%
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sodium hyaluronate without pranoprofen
Number of subjects: 60
Study: 20461969

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Montelukast (MK) 10 mg/d
Number of subjects: 33
Study: 18657569

Group type: EXPERIMENTAL
Intervention: School-based drug abuse prevention program (12-hour class-based curriculum)
Number of subjects: 7079
Study: 15709845

Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Number of subjects: 227

Group type: COMPARATOR
Intervention: Pill placebo
Number of subjects: 227

Group type: COMPARATOR
Intervention: Pharmacotherapy with clinical management
Number of subjects: 227
Study: 11792333

Group type: EXPERIMENTAL
Intervention: Perindopril
Number of subjects: 212

Group type: COMPARATOR
Intervention: Captopril
Number of subjects: 212
Study: 10069784

Group type: EXPERIMENTAL
Intervention: Cardiovascular risk factors (smoking, serum total cholesterol, HDL cholesterol, blood pressure, body mass index, diabetes)
Number of subjects: 14786

Group type: EXPERIMENTAL
Intervention: Age-related increase in risk factor levels
Number of subjects: 14786

Group type: EXPERIMENTAL
Intervention: Differences in HDL cholesterol and smoking
Number of subjects: 14786
Study: 7547089

Group type: EXPERIMENTAL
Intervention: Tenidap sodium (120 mg day-1)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Tenidap sodium (single dose)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (single dose)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Tenidap sodium
Number of subjects: 18
Study: 2326032

Group type: EXPERIMENTAL
Intervention: Low-dose ketamine with diazepam, meperidine, and nitrous oxide
Number of subjects: 40

Group type: COMPARATOR
Intervention: Methohexital sodium
Number of subjects: 40
Study: 7284544

Group type: EXPERIMENTAL
Intervention: Experimental treatment (not specified)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control population
Number of subjects: 0
Study: 30985704

Group type: EXPERIMENTAL
Intervention: Active PBMT
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 27909031

Group type: EXPERIMENTAL
Intervention: Topical gel from flax seed oil
Number of subjects: 49

Group type: COMPARATOR
Intervention: Hand splint
Number of subjects: 49
Study: 26691413

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sprint Interval Training (SIT)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Comparison of HIIT and SIT
Number of subjects: 12
Study: 24467781

Group type: EXPERIMENTAL
Intervention: 8‐week group Cognitive Behavioural Therapy (CBT) treatment
Number of subjects: 18

Group type: COMPARATOR
Intervention: Waitlist (8‐week clinical monitoring preceding treatment)
Number of subjects: 18
Study: 22198452

Group type: EXPERIMENTAL
Intervention: Tetrabenazine (TBZ) 12.5-75 mg/d, titrated according to a fixed, flexible schedule
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 20633266

Group type: EXPERIMENTAL
Intervention: Capsimax (2 mg capsaicinoids in a microencapsulated matrix)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 17414459

Group type: EXPERIMENTAL
Intervention: CAF (cyclophosphamide, Adriamycin, and 5‐fluorouracil)
Number of subjects: 343

Group type: EXPERIMENTAL
Intervention: CAF/thiotepa, Adriamycin, vinblastine, and Halotestin (TsAVbH)
Number of subjects: 343

Group type: EXPERIMENTAL
Intervention: Duration of disease-free interval > or = 2 years
Number of subjects: 343

Group type: EXPERIMENTAL
Intervention: Duration of disease-free interval < 2 years
Number of subjects: 343
Study: 16382379

Group type: EXPERIMENTAL
Intervention: Electrical cardioversion
Number of subjects: 34

Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 34
Study: 12118626

Group type: EXPERIMENTAL
Intervention: Motivational enhancement program (group-based)
Number of subjects: 167

Group type: COMPARATOR
Intervention: Not applicable (control group)
Number of subjects: 167
Study: 10447523

Group type: EXPERIMENTAL
Intervention: Presence of microaneurysms
Number of subjects: 2424

Group type: EXPERIMENTAL
Intervention: Number of microaneurysms
Number of subjects: 2424
Study: 1293732

Group type: EXPERIMENTAL
Intervention: Ivermectin (single dose)
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: Ivermectin (multiple doses)
Number of subjects: 700
Study: 6703638

Group type: EXPERIMENTAL
Intervention: Metronidazole
Number of subjects: 108

Group type: COMPARATOR
Intervention: Ampicillin
Number of subjects: 108
Study: 30699151

Group type: EXPERIMENTAL
Intervention: Intravenous amphotericin B 1mg/kg for 2 weeks and oral Fluconazole 800mg daily for 10 weeks
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Ever being re‐admitted since discharge after hospital‐based management of CCM
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Self-perceived quality of life 50-75%
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Self-perceived quality of life >75%
Number of subjects: 112
Study: 29288137

Group type: EXPERIMENTAL
Intervention: Randomized controlled trial (RCT) group
Number of subjects: 82430

Group type: EXPERIMENTAL
Intervention: Men choosing treatment
Number of subjects: 82430

Group type: COMPARATOR
Intervention: Excluded men with advanced cancer/comorbidities
Number of subjects: 82430
Study: 27382816

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.5 µg/kg
Number of subjects: 80

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 80
Study: 25801892

Group type: EXPERIMENTAL
Intervention: Intensive regimen (IR) of cholecalciferol (300.000 UI at baseline and 50.000 UI/monthly)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Standard regimen (SR) of cholecalciferol (25.000 UI monthly)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Both regimens (IR and SR)
Number of subjects: 34
Study: 23719555

Group type: EXPERIMENTAL
Intervention: Vitamin K1 supplementation (n = 40)
Number of subjects: 857

Group type: COMPARATOR
Intervention: Placebo (control group, n = 49)
Number of subjects: 857

Group type: EXPERIMENTAL
Intervention: Low serum vitamin K1
Number of subjects: 857

Group type: EXPERIMENTAL
Intervention: Low serum vitamin K1 in antihypertension medication users
Number of subjects: 857
Study: 19932057

Group type: EXPERIMENTAL
Intervention: LDL-apheresis
Number of subjects: 21

Group type: COMPARATOR
Intervention: Usual Medical Care (UMC)
Number of subjects: 21
Study: 17982167

Group type: EXPERIMENTAL
Intervention: Propofol/remifentanil (PR)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sevoflurane/remifentanil (SR)
Number of subjects: 40
Study: 16600506

Group type: EXPERIMENTAL
Intervention: Naloxone hydrochloride (0.14 mg/kg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Saline (NaCl, 0.9%)
Number of subjects: 20
Study: 14551369

Group type: EXPERIMENTAL
Intervention: Pre-filled dialysers
Number of subjects: 23

Group type: COMPARATOR
Intervention: Dry dialysers
Number of subjects: 23
Study: 10808170

Group type: EXPERIMENTAL
Intervention: MF DPI 50 microg twice daily
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: MF DPI 100 microg twice daily
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 9228350

Group type: EXPERIMENTAL
Intervention: Inhaled salbutamol for 6 weeks, increased in stepwise fashion at 2-week intervals
Number of subjects: 19

Group type: COMPARATOR
Intervention: Identical placebo for 6 weeks
Number of subjects: 19
Study: 8497871

Group type: EXPERIMENTAL
Intervention: Ketoconazole (200 mg/day) with reduced cyclosporine doses
Number of subjects: 43

Group type: COMPARATOR
Intervention: Standard doses of cyclosporine
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Reduced doses of cyclosporine with ketoconazole
Number of subjects: 43
Study: 3027838

Group type: EXPERIMENTAL
Intervention: 100 mg itraconazole twice a day for five days
Number of subjects: 47

Group type: COMPARATOR
Intervention: 100 mg itraconazole once a day for five days
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 47
Study: 28877139

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Supportive Care (SC)
Number of subjects: 66
Study: 28369443

Group type: EXPERIMENTAL
Intervention: Integrated collaborative care intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 23907764

Group type: EXPERIMENTAL
Intervention: 40 IU intranasal insulin
Number of subjects: 48

Group type: COMPARATOR
Intervention: 30 mg oral cortisol
Number of subjects: 48

Group type: COMPARATOR
Intervention: Both insulin and cortisol
Number of subjects: 48

Group type: COMPARATOR
Intervention: Neither (placebo)
Number of subjects: 48
Study: 22272611

Group type: EXPERIMENTAL
Intervention: MK-0249 5-mg daily for 4 weeks
Number of subjects: 144

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study: 20369760

Group type: EXPERIMENTAL
Intervention: Group M: 2 ml of 0.5% hyperbaric bupivacaine plus morphine 100 microg plus fentanyl 15 microg, mixed in a syringe
Number of subjects: 48

Group type: COMPARATOR
Intervention: Group S: 2 ml of 0.5% bupivacaine followed by morphine 100 microg plus fentanyl 15 microg through a separate syringe
Number of subjects: 48
Study: 18662943

Group type: EXPERIMENTAL
Intervention: Switch to a combination of emtricitabine, didanosine and efavirenz for 48 weeks
Number of subjects: 158

Group type: COMPARATOR
Intervention: Continue zidovudine regimen
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 158
Study: 15728401

Group type: EXPERIMENTAL
Intervention: ACE inhibitors (n = 26, 1-2 mg/day temocapril or trandolapril)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Calcium-channel blockers (CCB, n = 23, 2.5-5 mg/day amlodipine)
Number of subjects: 49
Study: 12499343

Group type: EXPERIMENTAL
Intervention: Cholecalciferol 25 micro g/d
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Cholecalciferol 125 micro g/d
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Cholecalciferol 250 micro g/d
Number of subjects: 67

Group type: COMPARATOR
Intervention: Cholecalciferol 0 micro g/d (control)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Total input from all sources (supplement, food, tissue stores)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Tissue stores
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Current recommended vitamin D inputs
Number of subjects: 67
Study: 10584680

Group type: EXPERIMENTAL
Intervention: Mixture of type A and type F botulinum toxins (5 units each)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Type A botulinum toxin alone
Number of subjects: 54

Group type: COMPARATOR
Intervention: Type F botulinum toxin alone
Number of subjects: 54
Study: 8838194

Group type: EXPERIMENTAL
Intervention: Oral acyclovir (800 mg five times daily)
Number of subjects: 691

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 691
Study: 1497518

Group type: EXPERIMENTAL
Intervention: Subconjunctival injections of fluorouracil (4 to 6 injections for 10 days after surgery)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no fluorouracil injections)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Subconjunctival injections of fluorouracil
Number of subjects: 50
Study: 6614128

Group type: EXPERIMENTAL
Intervention: Neurodevelopmental treatment (NDT)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Nonspecific play intervention
Number of subjects: 4
Study: 30303695

Group type: EXPERIMENTAL
Intervention: Alpha-lipoic acid (ALA) 100 mg per day for 8 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (cellulose acetate 100 mg per day for 8 weeks)
Number of subjects: 60
Study: 29741661

Group type: EXPERIMENTAL
Intervention: Hepatitis B testing offered by CHCs
Number of subjects: 3733

Group type: EXPERIMENTAL
Intervention: Hepatitis C testing offered by CHCs
Number of subjects: 3733

Group type: EXPERIMENTAL
Intervention: Perception of benefits for providing hepatitis testing
Number of subjects: 3733

Group type: EXPERIMENTAL
Intervention: Barriers for not offering hepatitis testing
Number of subjects: 3733

Group type: EXPERIMENTAL
Intervention: Determinants for offering hepatitis B and C testing
Number of subjects: 3733
Study: 27892422

Group type: EXPERIMENTAL
Intervention: Tele‐6MWT
Number of subjects: 155
Study: 24266780

Group type: EXPERIMENTAL
Intervention: Cardiopulmonary bypass (CPB)
Number of subjects: 47

Group type: COMPARATOR
Intervention: No cardiopulmonary bypass (No CPB)
Number of subjects: 47
Study: 22951801

Group type: EXPERIMENTAL
Intervention: Psychotherapy program for treatment of co-dependence
Number of subjects: 142
Study: 19383224

Group type: EXPERIMENTAL
Intervention: Pre-operative oral administration of magnesium for 10 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intra-operative flush infusion of magnesium
Number of subjects: 0
Study: 17449998

Group type: EXPERIMENTAL
Intervention: PMG incorporating systematic graded exposure
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Usual PMG treatment
Number of subjects: 143

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 143
Study: 15223903

Group type: EXPERIMENTAL
Intervention: Immunoglobulin doses (four doses compared)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Transplant-related complications (graft-versus-host disease and repeated infections)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Baseline status
Number of subjects: 85
Study: 12095662

Group type: EXPERIMENTAL
Intervention: Maintenance contingency (N=55)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Noncontingent incentives (N=55)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Methadone maintenance after the study
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Maintenance contingency group
Number of subjects: 110
Study: 9619936

Group type: EXPERIMENTAL
Intervention: Ambulatory chemotherapy
Number of subjects: 500

Group type: COMPARATOR
Intervention: Bed rest in hospital
Number of subjects: 500

Group type: COMPARATOR
Intervention: Plaster-of-Paris jacket
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: PAS plus isoniazid for 18 months
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: PAS plus isoniazid plus streptomycin for the first three months
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Radical excision of the spinal lesion with bone graft
Number of subjects: 500

Group type: COMPARATOR
Intervention: Open debridement
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Short-course regimes based on isoniazid and rifampicin
Number of subjects: 500
Study: 7698688

Group type: EXPERIMENTAL
Intervention: Fatty test meal
Number of subjects: 7

Group type: COMPARATOR
Intervention: No test meal
Number of subjects: 7
Study: 2678230

Group type: EXPERIMENTAL
Intervention: Amidotrizoate
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Iopromide
Number of subjects: 16
Study: 53111

Group type: EXPERIMENTAL
Intervention: 35S-methimazole (MMI)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: 35S-propylthiouracil (PTU)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: 35S-carbimazole
Number of subjects: 55
Study: 30932797

Group type: EXPERIMENTAL
Intervention: Diet Quality Index-International (DQI-I) scores
Number of subjects: 1300

Group type: EXPERIMENTAL
Intervention: Gender and maternal education levels
Number of subjects: 1300
Study: 28039505

Group type: EXPERIMENTAL
Intervention: Telephone counseling added to a printed survivorship care plan
Number of subjects: 411

Group type: EXPERIMENTAL
Intervention: Counseling intervention
Number of subjects: 411

Group type: EXPERIMENTAL
Intervention: Intrinsic motivation
Number of subjects: 411

Group type: EXPERIMENTAL
Intervention: Competency
Number of subjects: 411

Group type: EXPERIMENTAL
Intervention: Decisional control
Number of subjects: 411
Study: 26320930

Group type: EXPERIMENTAL
Intervention: Identifying a place for care
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Having a medical condition
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Having depression
Number of subjects: 185

Group type: COMPARATOR
Intervention: Not being involved in care decisions
Number of subjects: 185
Study: 22674191

Group type: EXPERIMENTAL
Intervention: Goserelin
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Bicalutamide
Number of subjects: 28

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Goserelin and Bicalutamide
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Endocrine treatment
Number of subjects: 28
Study: 21476025

Group type: EXPERIMENTAL
Intervention: MTA participants
Number of subjects: 788

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 788
Study: 18642207

Group type: EXPERIMENTAL
Intervention: DALK
Number of subjects: 732

Group type: COMPARATOR
Intervention: PKP
Number of subjects: 732
Study: 16517325

Group type: EXPERIMENTAL
Intervention: Butorphanol (30 microg kg(‐1)) and thiopentone
Number of subjects: 104

Group type: COMPARATOR
Intervention: Fentanyl (1.5 microg kg(‐1)) and thiopentone
Number of subjects: 104
Study: 12652055

Group type: EXPERIMENTAL
Intervention: Weekly folic acid supplement (2,800 microg)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Daily folic acid supplement (400 microg)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138
Study: 11101478

Group type: EXPERIMENTAL
Intervention: Polydextrose 12 g plus 50 g glucose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Polydextrose intake
Number of subjects: 0
Study: 8610862

Group type: EXPERIMENTAL
Intervention: 20 mg metoclopramide
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 60
Study: 1306643

Group type: EXPERIMENTAL
Intervention: Postexercise breast milk
Number of subjects: 26

Group type: COMPARATOR
Intervention: Pre-exercise breast milk
Number of subjects: 26